You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

269 Results
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Guidelines and Advice
Status: Current
ID: 7-A-2018-2
Version: N/A
Jan 2020
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2023
Cancer facts
Jul 2020
Document
Dec 2020
Document
Jan 2021
Document
Jan 2021
Guidelines and Advice
Status: Current
ID: 7-A-2018-3
Feb 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2024

Pages